Related Posts
10Dec
Privo Technologies receives 2015 TechConnect Innovation Award
Privo Technologies received the “2015 National Innovation Award” from the TechConnect World Innovation Conference. Privo’s ChemoThin Wafer project was... read more
10Dec
Privo Technologies Opens New Lab Facility in Peabody, MA
Privo Technologies expands to a new 3,000 square foot facility just outside of Boston, MA. Located at 200 Corporate... read more
04Feb
Privo Technologies, Inc. To Present at the 24th Annual BIO CEO & Investor Conference
Peabody, MA– Privo Technologies, Inc. (“Privo”), a clinical-stage biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on... read more
06Jun
BIO International Convention
Privo Technologies attends BIO International Convention as an invited guest of the National Institute of Dental and Craniofacial Research... read more
25Feb
Privo Technologies, Inc. Awarded $2.5M from National Cancer Institute for its Intraoperative Treatment of Solid Tumors
Peabody, MA — Privo Technologies, Inc. (“Privo”, “the Company”), a clinical stage biopharmaceutical company focused on optimizing state-of-the-art oncology treatments... read more
10Jan
Honored at the White House Privo Technologies receives the 2016 National Tibbetts Award
Privo Technologies is pleased to announce that the company has won the 2016 National Tibbetts award for outstanding contributions... read more
30Jun
Privo Technologies Announces the Appointment of Dr. James Mackay to Its Board of Directors
Privo Technologies (Privo), a Leader in the Field of Novel, Nanotechnology-Based Localized Oncology Treatments, is Pleased to Announce the... read more
07Oct
BioNetwork Partnering Summit
Privo CEO, Dr. Manijeh Goldberg, is invited to speak at the BioNetwork Partnering Summit. read more
20Aug
Privo Technologies, Inc. Awarded $3M NIDCR NIH Commercialization Readiness Pilot Grant
Peabody, MA -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer,... read more
22Oct
Privo Technologies, Inc. Announces Positive Results From Phase 1/2 Clinical Trial for PRV111 in Head and Neck Squamous Cell Carcinoma
PEABODY, Mass., October 22, 2021 --Privo Technologies, Inc. ("Privo"), announced today the positive results of their Phase 1/2 clinical trial... read more
- © Web Design & Development
- © UX Strategy & Digital Branding
